NCT02028819No Longer Available不适用
Compassionate Use of Ibalizumab for the Treatment of HIV Infection
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab has completed phase I and II clinical studies in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.
详细描述
- Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab is in the pipeline for FDA approval to treat HIV infection. Phase I and II clinical studies have been completed in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.
- Use of this medication requires that a single patient IND be obtained from the FDA for each patient requiring ibalizumab. An individual use IND has been approved by the FDA for one patient on treatment through this protocol; The IND number is 114515. The manufacturer of ibalizumab (TaiMed Biologics, Inc) will ship the drug directly to the Denver Health pharmacy.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with a diagnosis of HIV-infection with resistance or intolerance to currently available antiretroviral medications available in the United States or in whom additional drugs need to be added to their regimen because of inadequate response to existing therapy
- •Patients with HIV infection that is expected to be sensitive to dolutegravir and ibalizumab
- •Patients who do not qualify for or who are otherwise ineligible for clinical trials of medications not currently approved for treatment of HIV infection in the U.S.
排除标准
- •Patients who are allergic to or have had a severe adverse reaction to dolutegravir or ibalizumab in the past.
- •Age <18 years or >89 years
- •Women may not be pregnant
- •Prisoners and decisionally challenged patients will be excluded
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1HIVNCT00784147TaiMed Biologics Inc.113
Unknown
2 期
Omalizumab in Non-atopic AsthmaBronchial AsthmaNCT01113437King's College London40
已完成
3 期
Atezolizumab Trial in Endometrial Cancer - AtTEndEndometrial CancerNCT03603184Mario Negri Institute for Pharmacological Research549
已完成
4 期
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After DiscontinuationRheumatoid ArthritisNCT01120366SURPRISE Study Group233
已完成
2 期
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.Rheumatoid ArthritisNCT00034203XOMA (US) LLC